Cardiology Emergency Medicine Strong — validated in >40,000 patients
TIMI Risk Score for STEMI
Predicts 30-day mortality in ST-elevation myocardial infarction (STEMI).
Used in: Acute Coronary Syndrome & Chest Pain
Score interpretation
Low Risk 0–3
Score 0–3: 30-day mortality <3%. Lowest risk group.
→ Standard STEMI management. Primary PCI if within time window.
Intermediate Risk 4–6
Score 4–6: 30-day mortality 5–15%. Intermediate risk.
→ Primary PCI. Consider early intensive monitoring.
High Risk 7–14
Score ≥7: 30-day mortality >15–35%. High-risk STEMI.
→ Urgent primary PCI. Senior/consultant involvement. Consider early IABP if haemodynamically unstable.
Interpretation bands for the TIMI STEMI. Apply clinical judgement and local guidance.
References
- Morrow DA et al. TIMI risk score for ST-elevation myocardial infarction. Circulation. 2000.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Alteplase (STEMI Thrombolysis) · Thrombolytic / STEMI
- Streptokinase (STEMI Thrombolysis) · Thrombolytic / STEMI
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Tenecteplase (TNK-tPA — STEMI/Massive PE) · Fibrin-Specific Thrombolytic (Third-Generation tPA)
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.